POLD1 and cancer: Both variants were classified as likely pathogenic according to gene-specific variant recommendation for non-disruptive variants located in the exonuclease domain of POLD1 (12), and this interpretation was independently validated by the French expert group on genetics and cancer (Groupe Génétique et Cancer, GGC).